Merck & Company Inc (MRK) stock price

Merck & Company Inc (MRK) is a Healthcare · Drug Manufacturers - General company listed on NYSE. Price $146.87 (-0.19%), Market cap $286.20B, P/E ratio 32.64, 52-week low–high $76.17 ~ $123.93.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent

Key metrics

• Price: $146.87 (-0.19%)
• Market cap: $286.20B
• P/E ratio: 32.64
• 52-week low–high: $76.17 ~ $123.93
• Sector: Healthcare
• Industry: Drug Manufacturers - General
• Exchange: NYSE

Financial statements, price targets, institutional (13F) holdings and related news for Merck & Company Inc are updated in real time on BlackAll Trade.

Merck & Company Inc financial summary

Analyst outlook

• Analyst consensus: 4.0385
• Average price target: $101.40
• Rating distribution: Buy 15 · Hold 11 · Sell 0

Key ratios · profitability · growth

• P/B ratio: 6.08
• P/S ratio: 3.38
• PEG: 0.80
• Return on equity: 0.35%
• Return on assets: 0.13%
• Profit margin: 0.14%
• Operating margin: 0.39%
• Dividend yield: 0.03%
• Payout ratio: 0.42%

Merck & Company Inc investor discussion

9 recent posts · 9 bullish · 0 bearish · 0 neutral.

• [Bullish] MRK Keytruda 특허 만료 대비 파이프라인 확장 좋아보임. PER 15배면 헬스케어 내에서 싼 듯
• [Bullish] MRK Keytruda 특허 만료 대비 파이프라인 확장 좋아보임. PER 15배면 헬스케어 내에서 싼 듯
• [Bullish] MRK, Keytruda 특허 만료 대비한 파이프라인 확장 좋아보임. PER 15배면 헬스케어 내에서 싼 듯
• [Bullish] MRK는 Keytruda 특허 만료 전에 파이프라인 확장으로 대비하는 게 인상적임. PER 15배면 헬스케어 섹터 내에서 저평가된 듯
• [Bullish] MRK는 Keytruda 특허 만료 전에 파이프라인 확장으로 대비하는 게 인상적임. PER 15배면 헬스케어 섹터 내에서 저평가된 듯

Frequently asked questions